Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death
Various studies indicate that vaccination, especially with pneumococcal vaccines, protects against symptomatic cases of SARS-CoV-2 infection and death. This paper explores the possibility that pneumococcal vaccines in particular, but perhaps other vaccines as well, contain antigens that might be cro...
Main Author: | Robert Root-Bernstein |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/8/4/559 |
Similar Items
-
Pneumococcal whole-cell and protein-based vaccines: changing the paradigm
by: Michael E. Pichichero
Published: (2017-12-01) -
Recent progress in pneumococcal protein vaccines
by: Sha Li, et al.
Published: (2023-09-01) -
Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines
by: Ninecia R. Scott, et al.
Published: (2021-03-01) -
Pneumococcal Serogroups Causing the Most of the Invasive Diseases in Kayseri
by: Duygu EŞEL, et al.
Published: (2002-03-01) -
Adult pneumococcal vaccination – new opportunities
by: ERNEST KUCHAR, et al.
Published: (2023-03-01)